Cadrenal receives FDA guidance for phase 3 trial of HIT treatment

April 30, 2026 8:30 AM

Cadrenal Therapeutics Inc. (NASDAQ: CVKD) announced it completed an end-of-phase 2 meeting with the U.S. Food and Drug Administration and ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found